Forte Biosciences: 2026 Is Major Inflection Point For FB102

Terry ChrisomalisInvesting Group LeaderFollow5ShareSavePlay(17min)CommentsSummaryI initiate Forte Biosciences (FBRX) at a 'Hold' rating due to both pipeline risk and upcoming clinical catalysts.FB102, the lead anti-CD122 antibody, showed statistically significant phase 1b efficacy in celiac disease, with pivotal phase 2 data expected in 2026.The company's sole dependence on FB102 heightens risk, but additional readouts in vitiligo and alopecia areata provide potential upside.Recent financings extend cash runway, but competitive threats and trial outcome uncertainty warrant a balanced, risk-aware stance.Looking for a portfolio of ideas like this one? Members of Biotech Analysis Central get exclusive access to our subscriber-only portfolios. Learn More » Bordinthorn Loyrat/iStock via Getty Images I'm initiating Forte Biosciences (FBRX) with a "Hold" rating. The reason why I'm doing so is because even though in the past it had a rough failure with another candidate by the name of FB401This article was written byTerry Chrisomalis14.82K FollowersFollowTerry Chrisomalis is a private investor in the Biotech sector with years of experience utilizing his Applied Science background to generate long term value from Healthcare. He is the author of the investing group Biotech Analysis Central which contains a library of 600+ Biotech investing articles, a model portfolio of 10+ small and mid-cap stocks with deep analysis for each, live chat, and a range of analysis and news reports to help Healthcare investors make informed decisions.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.